RU2019125027A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019125027A3 RU2019125027A3 RU2019125027A RU2019125027A RU2019125027A3 RU 2019125027 A3 RU2019125027 A3 RU 2019125027A3 RU 2019125027 A RU2019125027 A RU 2019125027A RU 2019125027 A RU2019125027 A RU 2019125027A RU 2019125027 A3 RU2019125027 A3 RU 2019125027A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861198P | 2013-08-01 | 2013-08-01 | |
| US61/861,198 | 2013-08-01 | ||
| US201361901732P | 2013-11-08 | 2013-11-08 | |
| US61/901,732 | 2013-11-08 | ||
| US201461933632P | 2014-01-30 | 2014-01-30 | |
| US61/933,632 | 2014-01-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016106101A Division RU2698061C2 (ru) | 2013-08-01 | 2014-07-31 | АФУКОЗИЛИРОВАННЫЕ АНТИТЕЛА К РЕЦЕПТОРУ ФАКТОРА РОСТА ФИБРОБЛАСТОВ FGFR2IIIb |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019125027A RU2019125027A (ru) | 2019-08-19 |
| RU2019125027A3 true RU2019125027A3 (ru) | 2020-02-28 |
| RU2740714C2 RU2740714C2 (ru) | 2021-01-20 |
Family
ID=51358085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019125027A RU2740714C2 (ru) | 2013-08-01 | 2014-07-31 | Афукозилированные антитела к рецептору фактора роста фибробластов fgfr2iiib |
| RU2016106101A RU2698061C2 (ru) | 2013-08-01 | 2014-07-31 | АФУКОЗИЛИРОВАННЫЕ АНТИТЕЛА К РЕЦЕПТОРУ ФАКТОРА РОСТА ФИБРОБЛАСТОВ FGFR2IIIb |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016106101A RU2698061C2 (ru) | 2013-08-01 | 2014-07-31 | АФУКОЗИЛИРОВАННЫЕ АНТИТЕЛА К РЕЦЕПТОРУ ФАКТОРА РОСТА ФИБРОБЛАСТОВ FGFR2IIIb |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US20150050273A1 (ru) |
| EP (3) | EP3708583B1 (ru) |
| JP (4) | JP6860342B2 (ru) |
| KR (2) | KR20230047508A (ru) |
| CN (2) | CN112225810A (ru) |
| AU (3) | AU2014296174B2 (ru) |
| CA (1) | CA2915665C (ru) |
| CL (2) | CL2016000221A1 (ru) |
| CY (1) | CY1121517T1 (ru) |
| DK (2) | DK3708583T3 (ru) |
| ES (2) | ES2719103T3 (ru) |
| HK (1) | HK1220211A1 (ru) |
| HR (1) | HRP20190502T1 (ru) |
| HU (2) | HUE058243T2 (ru) |
| IL (1) | IL243409B (ru) |
| LT (2) | LT3708583T (ru) |
| ME (1) | ME03476B (ru) |
| MX (2) | MX2016001236A (ru) |
| MY (1) | MY184628A (ru) |
| NZ (1) | NZ715201A (ru) |
| PE (2) | PE20160190A1 (ru) |
| PH (2) | PH12016500137A1 (ru) |
| PL (2) | PL3027651T3 (ru) |
| PT (2) | PT3027651T (ru) |
| RS (1) | RS58719B1 (ru) |
| RU (2) | RU2740714C2 (ru) |
| SG (1) | SG11201600767UA (ru) |
| SI (2) | SI3708583T1 (ru) |
| TW (2) | TWI633120B (ru) |
| WO (1) | WO2015017600A1 (ru) |
| ZA (1) | ZA201603218B (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3708583T3 (da) | 2013-08-01 | 2022-05-16 | Five Prime Therapeutics Inc | Ikke-fucosylerede anti-fgfr2iiib-antistoffer |
| JP6446044B2 (ja) * | 2013-11-05 | 2018-12-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 結合分子の存在下で被検体の総量および／または総濃度を決定するための方法、ならびにそれに関係するキット、組成物および使用 |
| EP3287522A4 (en) * | 2015-04-20 | 2019-03-27 | Daiichi Sankyo Company, Limited | DETECTION OF FGFR2 |
| CN108368174B (zh) * | 2015-11-23 | 2023-04-14 | 戊瑞治疗有限公司 | 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合 |
| CN118416216A (zh) * | 2017-05-16 | 2024-08-02 | 戊瑞治疗有限公司 | 癌症治疗中抗fgfr2抗体与化学治疗剂的组合 |
| US11389480B2 (en) | 2017-05-19 | 2022-07-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting TNFR2 for cancer immunotherapy |
| CN111094352A (zh) | 2017-08-25 | 2020-05-01 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| AU2019226009A1 (en) | 2018-02-21 | 2020-09-03 | Five Prime Therapeutics, Inc. | B7-H4 antibody dosing regimens |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| AU2019228600A1 (en) | 2018-03-02 | 2020-09-24 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| CN112804989A (zh) * | 2018-10-05 | 2021-05-14 | 戊瑞治疗有限公司 | 抗fgfr2抗体制剂 |
| WO2020081497A1 (en) | 2018-10-15 | 2020-04-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| CN114901692A (zh) * | 2019-12-24 | 2022-08-12 | 迪哲(江苏)医药股份有限公司 | 新颖抗fgfr2b抗体 |
| AU2020412088A1 (en) * | 2019-12-24 | 2022-06-23 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-FGFR2b antibodies |
| WO2021129656A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| BR112022016720A2 (pt) | 2020-03-06 | 2022-11-16 | Ona Therapeutics S L | Anticorpos anti-cd36 e seu uso para tratamento de câncer |
| KR20230129456A (ko) * | 2020-12-29 | 2023-09-08 | 선전 포워드 파머수티컬즈 코 엘티디 | 항-fgfr2 항체 및 이의 용도 |
| CN118488964A (zh) | 2021-07-30 | 2024-08-13 | Ona疗法有限公司 | 抗cd36抗体及其治疗癌症的用途 |
| TW202342527A (zh) | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
| WO2024067876A1 (en) * | 2022-09-30 | 2024-04-04 | 3H Pharmaceuticals Co., Ltd. | Anti-fgfr2b antibodies and uses thereof |
| CN117917435A (zh) * | 2022-10-21 | 2024-04-23 | 北京天广实生物技术股份有限公司 | 结合fgfr2b的抗体及其用途 |
| WO2024140834A1 (en) * | 2022-12-28 | 2024-07-04 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-fgfr2b antibody and uses thereof |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| JP3039802B2 (ja) | 1989-07-06 | 2000-05-08 | ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア | 繊維芽細胞成長因子のための受容体 |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6323316B1 (en) | 1996-06-18 | 2001-11-27 | The United States Of America As Represented By The Secretary Of The Department Of And Human Services | Fibroblast growth factor receptor activating gene 1 and related compositions and methods |
| CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1185559A2 (en) | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| JP2001302699A (ja) | 2000-04-17 | 2001-10-31 | Nichirei Corp | ヒトｋｇｆｒに対する抗体 |
| EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
| NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CN101357943A (zh) * | 2001-10-25 | 2009-02-04 | 杰南技术公司 | 糖蛋白组合物 |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| DK1469878T3 (da) | 2002-01-31 | 2011-07-18 | Max Planck Gesellschaft | FGFR agonister |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003236015A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| KR100493460B1 (ko) | 2002-08-29 | 2005-06-07 | 재단법인서울대학교산학협력재단 | 암 세포에서 발현되는 ｆｇｆｒ2 이성체 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
| KR100973564B1 (ko) * | 2003-05-02 | 2010-08-03 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 및 그의 제조 방법 |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| ATE506077T1 (de) * | 2003-10-16 | 2011-05-15 | Imclone Llc | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
| US8268582B2 (en) | 2003-10-22 | 2012-09-18 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| WO2005066211A2 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| EP1773305A2 (en) | 2004-05-25 | 2007-04-18 | Yale University Corporation | Method for treating skeletal disorders resulting from fgfr malfunction |
| WO2006081430A2 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| US8207303B2 (en) * | 2005-02-18 | 2012-06-26 | Medarex, Inc. | Monoclonal antibodies against CD30 lacking in fucosyl residues |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| CA2648021A1 (en) | 2006-03-31 | 2007-10-11 | Ordway Research Institute, Inc. | Prognostic and diagnostic method for cancer therapy |
| CA2651755A1 (en) | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| EP2035034A4 (en) * | 2006-06-09 | 2009-11-18 | Univ Maryland | GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY |
| WO2007144893A2 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| CA2664738C (en) | 2006-09-29 | 2017-03-07 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| JP5570218B2 (ja) | 2006-11-03 | 2014-08-13 | ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｆｇｆｒ４抗体 |
| AR063975A1 (es) | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008079849A2 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| US7994290B2 (en) | 2007-01-24 | 2011-08-09 | Kyowa Hakko Kirin Co., Ltd | Effector function enhanced recombinant antibody composition |
| KR20100015883A (ko) | 2007-03-23 | 2010-02-12 | 더 트랜스내셔날 게노믹스 리서치 인스티튜트 | 자궁내막암 및 전암을 진단，분류 및 치료하는 방법 |
| WO2008121876A2 (en) * | 2007-03-28 | 2008-10-09 | Biogen Idec Inc. | Non-fucosylated antibodies |
| EP2205277B1 (en) | 2007-10-22 | 2017-07-26 | Genmab A/S | Novel antibody therapies |
| WO2009100105A2 (en) | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
| US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| WO2009119173A1 (ja) | 2008-03-26 | 2009-10-01 | 日本電気株式会社 | 無線リソースの制御方法、無線局装置、無線局制御プログラムを格納した記録媒体、及び無線通信システム |
| EP2285984A1 (en) * | 2008-06-10 | 2011-02-23 | University Of Southern California | Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| KR101699432B1 (ko) | 2008-11-07 | 2017-01-24 | 갤럭시 바이오테크, 엘엘씨 | 섬유아세포성장인자수용체 ２에 대한 모노클로날 항체 |
| WO2011025814A1 (en) | 2009-08-25 | 2011-03-03 | National Jewish Health | Methods and compositions for treatment of lung injury |
| US9096877B2 (en) * | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| AU2010313621C1 (en) * | 2009-10-14 | 2015-11-26 | Humanigen, Inc. | Antibodies to EphA3 |
| CA2786276A1 (en) | 2010-01-14 | 2011-07-21 | Yale University | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| EP2547698B1 (en) | 2010-03-14 | 2015-07-29 | The Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| NZ603972A (en) | 2010-05-11 | 2014-11-28 | Aveo Pharmaceuticals Inc | Anti-fgfr2 antibodies |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2603521A4 (en) | 2010-08-12 | 2014-10-01 | Attogen Inc | ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES |
| US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
| EP3219731A1 (en) * | 2010-10-01 | 2017-09-20 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013087716A2 (de) | 2011-12-14 | 2013-06-20 | Bayer Pharma Aktiengesellschaft | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
| DK2831110T3 (en) * | 2012-03-30 | 2018-08-06 | Univ California | Anti-EMP2 therapy to reduce cancer stem cells |
| WO2013154206A1 (ja) | 2012-04-09 | 2013-10-17 | 第一三共株式会社 | 抗ｆｇｆｒ２抗体 |
| US9254288B2 (en) | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2014007369A1 (ja) | 2012-07-05 | 2014-01-09 | 独立行政法人国立がん研究センター | Ｆｇｆｒ２融合遺伝子 |
| WO2014089193A1 (en) | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| RU2015150233A (ru) | 2013-05-01 | 2017-06-02 | Файв Прайм Терапьютикс, Инк. | Способы лечения злокачественной опухоли |
| EP3008210B1 (en) | 2013-06-13 | 2020-10-07 | University Of South Australia | Methods for detecting prostate cancer |
| DK3708583T3 (da) | 2013-08-01 | 2022-05-16 | Five Prime Therapeutics Inc | Ikke-fucosylerede anti-fgfr2iiib-antistoffer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2015116868A2 (en) | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN108368174B (zh) | 2015-11-23 | 2023-04-14 | 戊瑞治疗有限公司 | 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合 |
-
2014
- 2014-07-31 DK DK19151147.6T patent/DK3708583T3/da active
- 2014-07-31 DK DK14752705.5T patent/DK3027651T3/en active
- 2014-07-31 RU RU2019125027A patent/RU2740714C2/ru active
- 2014-07-31 EP EP19151147.6A patent/EP3708583B1/en active Active
- 2014-07-31 SG SG11201600767UA patent/SG11201600767UA/en unknown
- 2014-07-31 WO PCT/US2014/049008 patent/WO2015017600A1/en active Application Filing
- 2014-07-31 CN CN202010986598.1A patent/CN112225810A/zh active Pending
- 2014-07-31 KR KR1020237010509A patent/KR20230047508A/ko not_active Application Discontinuation
- 2014-07-31 RS RS20190588A patent/RS58719B1/sr unknown
- 2014-07-31 ES ES14752705T patent/ES2719103T3/es active Active
- 2014-07-31 CA CA2915665A patent/CA2915665C/en active Active
- 2014-07-31 RU RU2016106101A patent/RU2698061C2/ru active
- 2014-07-31 PE PE2016000119A patent/PE20160190A1/es unknown
- 2014-07-31 LT LTEP19151147.6T patent/LT3708583T/lt unknown
- 2014-07-31 HU HUE19151147A patent/HUE058243T2/hu unknown
- 2014-07-31 KR KR1020167005003A patent/KR102516152B1/ko active IP Right Grant
- 2014-07-31 US US14/447,751 patent/US20150050273A1/en not_active Abandoned
- 2014-07-31 PE PE2021000044A patent/PE20210949A1/es unknown
- 2014-07-31 ME MEP-2019-142A patent/ME03476B/me unknown
- 2014-07-31 JP JP2016531878A patent/JP6860342B2/ja active Active
- 2014-07-31 AU AU2014296174A patent/AU2014296174B2/en active Active
- 2014-07-31 TW TW103126289A patent/TWI633120B/zh active
- 2014-07-31 EP EP14752705.5A patent/EP3027651B1/en active Active
- 2014-07-31 PT PT14752705T patent/PT3027651T/pt unknown
- 2014-07-31 MX MX2016001236A patent/MX2016001236A/es active IP Right Grant
- 2014-07-31 PL PL14752705T patent/PL3027651T3/pl unknown
- 2014-07-31 ES ES19151147T patent/ES2913291T3/es active Active
- 2014-07-31 PL PL19151147T patent/PL3708583T3/pl unknown
- 2014-07-31 MY MYPI2016000176A patent/MY184628A/en unknown
- 2014-07-31 EP EP22151171.0A patent/EP4036118A1/en active Pending
- 2014-07-31 LT LTEP14752705.5T patent/LT3027651T/lt unknown
- 2014-07-31 SI SI201431949T patent/SI3708583T1/sl unknown
- 2014-07-31 TW TW107125185A patent/TWI679021B/zh active
- 2014-07-31 NZ NZ715201A patent/NZ715201A/en unknown
- 2014-07-31 CN CN201480043427.8A patent/CN105452296B/zh active Active
- 2014-07-31 PT PT191511476T patent/PT3708583T/pt unknown
- 2014-07-31 HU HUE14752705A patent/HUE043815T2/hu unknown
- 2014-07-31 SI SI201431132T patent/SI3027651T1/sl unknown
-
2015
- 2015-12-29 IL IL24340915A patent/IL243409B/en active IP Right Grant
-
2016
- 2016-01-15 ZA ZA2016/03218A patent/ZA201603218B/en unknown
- 2016-01-21 PH PH12016500137A patent/PH12016500137A1/en unknown
- 2016-01-28 MX MX2020009223A patent/MX2020009223A/es unknown
- 2016-01-28 CL CL2016000221A patent/CL2016000221A1/es unknown
- 2016-05-27 US US15/166,798 patent/US10172937B2/en active Active
- 2016-07-14 HK HK16108257.3A patent/HK1220211A1/zh unknown
-
2018
- 2018-08-10 CL CL2018002291A patent/CL2018002291A1/es unknown
- 2018-11-06 US US16/181,784 patent/US11235059B2/en active Active
-
2019
- 2019-03-13 HR HRP20190502TT patent/HRP20190502T1/hr unknown
- 2019-04-05 CY CY20191100382T patent/CY1121517T1/el unknown
- 2019-06-18 PH PH12019501393A patent/PH12019501393A1/en unknown
- 2019-07-17 AU AU2019206039A patent/AU2019206039B2/en active Active
- 2019-10-25 JP JP2019194319A patent/JP7183136B2/ja active Active
-
2021
- 2021-10-07 AU AU2021245169A patent/AU2021245169A1/en active Pending
- 2021-12-17 US US17/554,423 patent/US20220168416A1/en active Pending
-
2022
- 2022-02-14 JP JP2022020496A patent/JP2022078080A/ja active Pending
- 2022-11-21 JP JP2022185432A patent/JP2023018049A/ja active Pending